Descriptive epidemiology of cancer of unknown primary in South Korea, 1999–2017

Boo, Yoo-Kyung; Park, Dayeon; Lim, Jiwon; Lim, Hyun-Sook; Won, Young‐Joo

doi:10.1016/j.canep.2021.102000

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Historical studies have estimated that CUP accounts for 3%–5% of all new cancer cases; however, the exact incidence rate is difficult to determine for various objective reasons 6 . In the current era, several studies have reported a decreasing trend for the occurrence of CUP with incidence rates of 1%–2% 6–8 . The declining incidence of CUP is considered to be closely related to the development of diagnostic technologies, such as radiology, histopathology, and genetic testing, which are also reflected in improved completeness and validity of the cancer registration data 9 .…”

Section: Introductionmentioning

confidence: 99%

“… 6 In the current era, several studies have reported a decreasing trend for the occurrence of CUP with incidence rates of 1%–2%. 6 , 7 , 8 The declining incidence of CUP is considered to be closely related to the development of diagnostic technologies, such as radiology, histopathology, and genetic testing, which are also reflected in improved completeness and validity of the cancer registration data. 9 However, previous CUP epidemiological studies have focused on Sweden, Netherlands, Scotland, and United States.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases

Pan

Sun²,

Liu

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Cancer of unknown primary (CUP) is defined the presence of metastatic disease without an identified primary site. An unidentifiable primary site of cancer creates significant challenges for treatment selection. We aimed to describe the clinicopathological, molecular, and prognostic characteristics of Chinese CUP patients. Methods Patients with oncologist‐confirmed CUP were identified at Fudan University Shanghai Cancer Center from 2019 to 2020. Information on patient characteristics, tumor presentation, treatment, and outcome were retrospectively collected from the inpatient database and pathological consultation database for descriptive analysis. A multivariable logistic regression model was established to identify factors associated with patient prognosis. Results A total of 1420 CUP patients were enrolled in this study. The baseline characteristics of the entire cohort included the following: median age (59 years old), female sex (45.8%), adenocarcinoma (47.7%), and poorly differentiated or undifferentiated tumors (92.1%). For the inpatient cohort, the most common sites where cancer spread included the lymph nodes (41.8%), bone (22.0%), liver (20.1%), and peritoneum/retroperitoneum (16.0%). A total of 77.4% and 58.2% of patients were treated with local therapy and systemic therapy, respectively. Four prognostic factors, including liver metastasis, peritoneal/retroperitoneal metastasis, number of metastatic sites (N ≥ 2), and systemic treatment, were independently associated with overall survival. Additionally, 24.8% (79/318) of patients received molecular testing, including PD‐L1, human papillomavirus, genetic variation, and 90‐gene expression tests for diagnosis or therapy selection. Conclusion Cancer of unknown primary remains a difficult cancer to diagnose and manage. Our findings improve our understanding of Chinese CUP patient characteristics, leading to improved care and outcomes for CUP patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases

Pan

Sun²,

Liu

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Patients aged 80 and up had the highest risk of occurrence. The survival rate climbed from 14.2% in 1999–2002 to 27.3% in 2013–2017 [ 13 ]. In Sweden, it is estimated that the age-standardised incidence increased from 10 per 100,000 in the early 1960s to 16 per 100,000 around the year 2000 for both males and females [ 14 ].…”

Section: Epidemiology Of Cupmentioning

confidence: 99%

From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary

Mathew

Aliyuda

Taiwo

et al. 2023

IJMS

View full text Add to dashboard Cite

Cancer of unknown primary (CUP) encloses a group of heterogeneous tumours, the primary sites for which cannot be identified at the time of diagnosis, despite extensive investigations. CUP has always posed major challenges both in its diagnosis and management, leading to the hypothesis that it is rather a distinct entity with specific genetic and phenotypic aberrations, considering the regression or dormancy of the primary tumour; the development of early, uncommon systemic metastases; and the resistance to therapy. Patients with CUP account for 1–3% of all human malignancies and can be categorised into two prognostic subsets according to their clinicopathologic characteristics at presentation. The diagnosis of CUP mainly depends on the standard evaluation comprising a thorough medical history; complete physical examination; histopathologic morphology and algorithmic immunohistochemistry assessment; and CT scan of the chest, abdomen, and pelvis. However, physicians and patients do not fare well with these criteria and often perform additional time-consuming evaluations to identify the primary tumour site to guide treatment decisions. The development of molecularly guided diagnostic strategies has emerged to complement traditional procedures but has been disappointing thus far. In this review, we present the latest data on CUP regarding the biology, molecular profiling, classification, diagnostic workup, and treatment.

show abstract

“…Cancers of unknown primary (CUP) form a heterogeneous group of metastatic tumours for which the source cannot be identi ed. 1,2 This largely limits options for treatment and, consequently, impairs patients' prognosis (van der Strate et al, 2021, manuscript in preparation). CUP patients have a median survival time of approximately 11 months, and only 20% survive more than one year following diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Factors among Patients with Brain Metastases from Cancer of Unknown Primary

Padilla

Leenders

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Cancer of an unknown primary (CUP) has a dismal prognosis, the situation is worse for CUP patients with brain metastases (BM-CUP). This study aimed provides better insight into BM-CUP occurrence and determinants of patients’ survival in a population-based setting. Methods Cases were selected from the Netherlands Cancer Registry (1,430 BM-CUP/17,140 CUP). Baseline characteristics between CUP patients with and without BM were tested using chi-square tests and Mann-Whitney U tests. Patients’ overall survival (OS) curves were estimated by the Kaplan-Meier method, and prognostic factors on OS was assessed using Cox proportional hazards regression analyses. Results The proportion of BM-CUP patients among CUP increased from 8% in 2009–2010 to 10% in 2017–2018 (p < 0.001). Most patients presented with multiple brain lesions (53%). Survival of BM-CUP improved over time: one-year OS increased from 10% for patients diagnosed in 2009–2010 to 17% (2017–2018) (p < 0.01), and median survival times increased from 1.8 months to 2.4 months. Aside from time period and elderly age, independent predictors of poor survival were multiple (HR 1.25; p < 0.01) or unknown (HR 1.48; p < 0.01) locations of BM, unknown/poorly/undifferentiated carcinoma histology (HR 1.53; p < 0.01), or clinical symptoms of BM (HR 1.74; p < 0.01), accompanying liver metastasis (HR 1.43; p < 0.01) and more than one metastatic site outside the brain compared to none (HR 1.52; p < 0.01). Conclusion This research contributes to better knowledge on BM-CUP patients. Comprehensive baseline information aids the implementation and evaluation of new diagnostic approaches, treatment protocols and supportive/palliative care guidelines thus improve patients’ quality of life.

show abstract

Descriptive epidemiology of cancer of unknown primary in South Korea, 1999–2017

Cited by 6 publications

References 31 publications

Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases

Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases

From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary

Prognostic Factors among Patients with Brain Metastases from Cancer of Unknown Primary

Contact Info

Product

Resources

About